Literature DB >> 22841784

Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.

Etienne Patin1, Zoltán Kutalik2, Julien Guergnon3, Stéphanie Bibert4, Bertrand Nalpas5, Emmanuelle Jouanguy6, Mona Munteanu7, Laurence Bousquet5, Laurent Argiro8, Philippe Halfon9, Anne Boland10, Beat Müllhaupt11, David Semela12, Jean-François Dufour13, Markus H Heim14, Darius Moradpour15, Andreas Cerny16, Raffaele Malinverni17, Hans Hirsch18, Gladys Martinetti19, Vijayaprakash Suppiah20, Graeme Stewart21, David R Booth21, Jacob George22, Jean-Laurent Casanova6, Christian Bréchot23, Charles M Rice24, Andrew H Talal25, Ira M Jacobson25, Marc Bourlière26, Ioannis Theodorou3, Thierry Poynard27, Francesco Negro28, Stanislas Pol5, Pierre-Yves Bochud29, Laurent Abel30.   

Abstract

BACKGROUND & AIMS: Polymorphisms in IL28B were shown to affect clearance of hepatitis C virus (HCV) infection in genome-wide association (GWA) studies. Only a fraction of patients with chronic HCV infection develop liver fibrosis, a process that might also be affected by genetic factors. We performed a 2-stage GWA study of liver fibrosis progression related to HCV infection.
METHODS: We studied well-characterized HCV-infected patients of European descent who underwent liver biopsies before treatment. We defined various liver fibrosis phenotypes on the basis of METAVIR scores, with and without taking the duration of HCV infection into account. Our GWA analyses were conducted on a filtered primary cohort of 1161 patients using 780,650 single nucleotide polymorphisms (SNPs). We genotyped 96 SNPs with P values <5 × 10(-5) from an independent replication cohort of 962 patients. We then assessed the most interesting replicated SNPs using DNA samples collected from 219 patients who participated in separate GWA studies of HCV clearance.
RESULTS: In the combined cohort of 2342 HCV-infected patients, the SNPs rs16851720 (in the total sample) and rs4374383 (in patients who received blood transfusions) were associated with fibrosis progression (P(combined) = 8.9 × 10(-9) and 1.1 × 10(-9), respectively). The SNP rs16851720 is located within RNF7, which encodes an antioxidant that protects against apoptosis. The SNP rs4374383, together with another replicated SNP, rs9380516 (P(combined) = 5.4 × 10(-7)), were linked to the functionally related genes MERTK and TULP1, which encode factors involved in phagocytosis of apoptotic cells by macrophages.
CONCLUSIONS: Our GWA study identified several susceptibility loci for HCV-induced liver fibrosis; these were linked to genes that regulate apoptosis. Apoptotic control might therefore be involved in liver fibrosis.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22841784      PMCID: PMC3756935          DOI: 10.1053/j.gastro.2012.07.097

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  44 in total

1.  Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma.

Authors:  Vinod Kumar; Naoya Kato; Yuji Urabe; Atsushi Takahashi; Ryosuke Muroyama; Naoya Hosono; Motoyuki Otsuka; Ryosuke Tateishi; Masao Omata; Hidewaki Nakagawa; Kazuhiko Koike; Naoyuki Kamatani; Michiaki Kubo; Yusuke Nakamura; Koichi Matsuda
Journal:  Nat Genet       Date:  2011-04-17       Impact factor: 38.330

2.  Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis.

Authors:  Nora B Caberoy; Yixiong Zhou; Wei Li
Journal:  EMBO J       Date:  2010-10-26       Impact factor: 11.598

3.  Hepatitis C virus inhibits DNA damage repair through reactive oxygen and nitrogen species and by interfering with the ATM-NBS1/Mre11/Rad50 DNA repair pathway in monocytes and hepatocytes.

Authors:  Keigo Machida; George McNamara; Kevin T-H Cheng; Jeffrey Huang; Chun-Hsiang Wang; Lucio Comai; Jing-Hsiung James Ou; Michael M C Lai
Journal:  J Immunol       Date:  2010-10-25       Impact factor: 5.422

4.  Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C.

Authors:  Eric Trépo; Pierre Pradat; Andrej Potthoff; Yukihide Momozawa; Eric Quertinmont; Thierry Gustot; Arnaud Lemmers; Pascale Berthillon; Leila Amininejad; Michéle Chevallier; Jerome Schlué; Hans Kreipe; Jacques Devière; Michael Manns; Christian Trépo; John Sninsky; Heiner Wedemeyer; Denis Franchimont; Christophe Moreno
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

5.  Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C.

Authors:  Luca Valenti; Mariagrazia Rumi; Enrico Galmozzi; Alessio Aghemo; Benedetta Del Menico; Stella De Nicola; Paola Dongiovanni; Marco Maggioni; Anna Ludovica Fracanzani; Raffaela Rametta; Massimo Colombo; Silvia Fargion
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

6.  Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease.

Authors:  Naga Chalasani; Xiuqing Guo; Rohit Loomba; Mark O Goodarzi; Talin Haritunians; Soonil Kwon; Jinrui Cui; Kent D Taylor; Laura Wilson; Oscar W Cummings; Yii-Der Ida Chen; Jerome I Rotter
Journal:  Gastroenterology       Date:  2010-08-11       Impact factor: 22.682

Review 7.  Apoptosis as a mechanism for liver disease progression.

Authors:  Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Semin Liver Dis       Date:  2010-10-19       Impact factor: 6.115

Review 8.  IL28B and the control of hepatitis C virus infection.

Authors:  Ashwin Balagopal; David L Thomas; Chloe L Thio
Journal:  Gastroenterology       Date:  2010-10-13       Impact factor: 22.682

9.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

10.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.

Authors:  Stefano Romeo; Julia Kozlitina; Chao Xing; Alexander Pertsemlidis; David Cox; Len A Pennacchio; Eric Boerwinkle; Jonathan C Cohen; Helen H Hobbs
Journal:  Nat Genet       Date:  2008-09-25       Impact factor: 38.330

View more
  53 in total

1.  Genomic Signatures of Selective Pressures and Introgression from Archaic Hominins at Human Innate Immunity Genes.

Authors:  Matthieu Deschamps; Guillaume Laval; Maud Fagny; Yuval Itan; Laurent Abel; Jean-Laurent Casanova; Etienne Patin; Lluis Quintana-Murci
Journal:  Am J Hum Genet       Date:  2016-01-07       Impact factor: 11.025

2.  HLA class II associated with outcomes of hepatitis B and C infections.

Authors:  Akihiro Tamori; Norifumi Kawada
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 3.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Authors:  Siddharth Singh; Alina M Allen; Zhen Wang; Larry J Prokop; Mohammad H Murad; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

4.  Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution.

Authors:  Jamie C Stanford; Christian Young; Donna Hicks; Philip Owens; Andrew Williams; David B Vaught; Meghan M Morrison; Jiyeon Lim; Michelle Williams; Dana M Brantley-Sieders; Justin M Balko; Debra Tonetti; H Shelton Earp; Rebecca S Cook
Journal:  J Clin Invest       Date:  2014-09-24       Impact factor: 14.808

5.  A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.

Authors:  Stephan Buch; Felix Stickel; Eric Trépo; Michael Way; Alexander Herrmann; Hans Dieter Nischalke; Mario Brosch; Jonas Rosendahl; Thomas Berg; Monika Ridinger; Marcella Rietschel; Andrew McQuillin; Josef Frank; Falk Kiefer; Stefan Schreiber; Wolfgang Lieb; Michael Soyka; Nasser Semmo; Elmar Aigner; Christian Datz; Renate Schmelz; Stefan Brückner; Sebastian Zeissig; Anna-Magdalena Stephan; Norbert Wodarz; Jacques Devière; Nicolas Clumeck; Christoph Sarrazin; Frank Lammert; Thierry Gustot; Pierre Deltenre; Henry Völzke; Markus M Lerch; Julia Mayerle; Florian Eyer; Clemens Schafmayer; Sven Cichon; Markus M Nöthen; Michael Nothnagel; David Ellinghaus; Klaus Huse; Andre Franke; Steffen Zopf; Claus Hellerbrand; Christophe Moreno; Denis Franchimont; Marsha Y Morgan; Jochen Hampe
Journal:  Nat Genet       Date:  2015-10-19       Impact factor: 38.330

6.  CUBN and NEBL common variants in the chromosome 10p13 linkage region are associated with multibacillary leprosy in Vietnam.

Authors:  Audrey V Grant; Aurelie Cobat; Nguyen Van Thuc; Marianna Orlova; Nguyen Thu Huong; Jean Gaschignard; Andrea Alter; Nguyen Ngoc Ba; Vu Hong Thai; Laurent Abel; Alexandre Alcaïs; Erwin Schurr
Journal:  Hum Genet       Date:  2014-02-23       Impact factor: 4.132

Review 7.  The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis.

Authors:  Amit G Singal; Hema Manjunath; Adam C Yopp; Muhammad S Beg; Jorge A Marrero; Purva Gopal; Akbar K Waljee
Journal:  Am J Gastroenterol       Date:  2014-01-21       Impact factor: 10.864

Review 8.  Management of HCV in cirrhosis-a rapidly evolving landscape.

Authors:  Suraj A Sharma; Jordan J Feld
Journal:  Curr Gastroenterol Rep       Date:  2015-05

9.  Identifying causal regulatory SNPs in ChIP-seq enhancers.

Authors:  Di Huang; Ivan Ovcharenko
Journal:  Nucleic Acids Res       Date:  2014-12-17       Impact factor: 16.971

Review 10.  Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?

Authors:  Youngmin A Lee; Scott L Friedman
Journal:  Antiviral Res       Date:  2014-04-12       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.